AKTIPAK
LOE ApproachingNDATOPICALGEL
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKTIPAK is a topical gel approved in 2000 by Biofrontera for dermatological use. The specific mechanism of action and indication are not disclosed in available data. This product represents a legacy dermatology asset in late-stage lifecycle.
LOE Approaching
LOE-approaching status suggests a shrinking commercial footprint with likely reduced team headcount and shift toward managed care optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AKTIPAK offers limited career growth opportunities given its LOE-approaching status and zero linked job postings. Roles on this product are primarily defensive, focused on maintaining market share during generic transition rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on AKTIPAK at Biofrontera? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.